Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Disease & Drugs

Clinical Trials

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Clinical Trials

1,156 stories · every one Fact-Checked
SELLAS SLS009 combination therapy with azacitidine and venetoclax showing response outcomes in TP53-mutated and relapsed/refractory AML.Clinical TrialsSELLAS Reports 57% Response Rate with SLS009 in TP53-Mutated AMLSELLAS reported Phase 2 findings for SLS009 combined with azacitidine and venetoclax in relapsed/refractory AML.5 Nov 2026 · 3 min read
Fact-Checked
Dapolsertib dual PIM FLT3 inhibitor under investigation in Phase II JASPIS-01 study for relapsed or refractory aggressive B-cell lymphoma.Clinical TrialsMenarini Reports Dapolsertib Activity in Heavily Pretreated B-Cell Lymphoma Ahead of ASH 2026Menarini and Ryvu Therapeutics report initial clinical activity for dapolsertib, an oral dual PIM/FLT3 inhibitor, in heavily pretreated patients with relapsed or refractory aggressive B-cell lymphoma in the…5 Nov 2026 · 4 min read
Fact-Checked
Taiho ASTX030 oral azacitidine and cedazuridine combination evaluated in the Phase 3 AZTOUND trial for MDS and CMML.Clinical TrialsTaiho’s ASTX030 Meets Phase 3 Endpoint in MDS and CMMLTaiho’s investigational oral combination ASTX030 demonstrated pharmacokinetic equivalence to subcutaneous azacitidine in the Phase 3 AZTOUND trial in patients with MDS or CMML.5 Nov 2026 · 4 min read
Fact-Checked
ADC Therapeutics ZYNLONTA clinical programme highlighting LOTIS-7, LOTIS-5 and Phase 2 marginal zone lymphoma study results ahead of ASH 2026.Clinical TrialsADC Highlights Strong ZYNLONTA Responses Across Three TrialsADC Therapeutics will present five oral abstracts at ASH 2026, featuring updated ZYNLONTA findings from LOTIS-7, LOTIS-5 and a Phase 2 marginal zone lymphoma study.4 Nov 2026 · 5 min read
Fact-Checked
Sanofi discontinues development of Nurix's oral STAT6 degrader SAR448272 after Phase 1 initiation.Clinical TrialsSanofi Terminates Nurix’s Oral STAT6 Degrader ProgrammeSanofi has terminated the Phase 1 clinical trial and development programme for Nurix’s oral STAT6 degrader SAR448272.4 Nov 2026 · 3 min read
Fact-Checked
Pfizer discontinues three investigational drug programmes targeting ITP, pulmonary arterial hypertension and obesity.Clinical TrialsPfizer Ends Development of Three Candidates in ITP, PAH and ObesityPfizer has discontinued three investigational drug programmes targeting ITP, pulmonary arterial hypertension and obesity.3 Nov 2026 · 4 min read
Fact-Checked
Hoth Therapeutics HT-001 topical aprepitant gel under investigation for EGFR inhibitor-associated skin toxicities.Clinical TrialsHoth Ends HT-001 Phase 2a Early, Plans FDA Talks on Potential Phase 3Hoth Therapeutics has concluded its Phase 2a trial of HT-001 ahead of schedule following positive interim efficacy findings.3 Nov 2026 · 4 min read
Fact-Checked
SER-155 live biotherapeutic approach targeting gastrointestinal microbiome disruption and bloodstream infections in stem cell transplant recipients.Clinical TrialsSeres Reports 77% Reduction in Bloodstream Infections With SER-155Seres Therapeutics’ investigational live biotherapeutic SER-155 was associated with a 77% relative reduction in bloodstream infections among allogeneic stem cell transplant recipients in a Phase 1b study.3 Nov 2026 · 4 min read
Fact-Checked
Merck Ohtuvayre ensifentrine Phase 3 ENHANCE-3 trial for COPD exacerbation preventionClinical TrialsMerck Advances Ohtuvayre into Phase 3 COPD Exacerbation TrialMerck has initiated the Phase 3 ENHANCE-3 trial to evaluate whether Ohtuvayre (ensifentrine), added to standard-of-care therapy, can reduce moderate or severe COPD exacerbations.3 Nov 2026 · 4 min read
Fact-Checked
Tiziana Life Sciences intranasal foralumab Phase 2a trial results in non-active secondary progressive multiple sclerosis.Clinical TrialsTiziana Reports Positive Phase 2a Results for Intranasal ForalumabTiziana Life Sciences reported positive Phase 2a INFORM-MS results for intranasal foralumab in non-active secondary progressive multiple sclerosis.3 Nov 2026 · 4 min read
Fact-Checked
GSK's depemokimab maintains asthma exacerbation control and symptom improvements over two years in patients with severe eosinophilic asthma.Clinical TrialsGSK Depemokimab Maintains Asthma Control Over Two YearsGSK’s twice-yearly depemokimab maintained reductions in asthma exacerbations, improvements in symptom control and suppression of blood eosinophils over two years.3 Nov 2026 · 5 min read
Fact-Checked
Incyte povorcitinib Phase 3 STOP-V1 and STOP-V2 trials showing facial repigmentation results in nonsegmental vitiligo.Clinical TrialsIncyte Reports Positive Results for Povorcitinib in Vitiligo TrialsIncyte’s povorcitinib met the primary endpoint in both Phase 3 STOP-V1 and STOP-V2 trials in nonsegmental vitiligo.3 Nov 2026 · 5 min read
Fact-Checked
Page 4 of 97